42 results on '"Santos-Laso Á"'
Search Results
2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
3. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma
4. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models
5. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
6. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
7. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
8. Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings
9. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease
10. THU-118 Prophylaxis for tuberculosis and pneumocystis jirovecii does not seem necessary in patients with autoimmune hepatitis treated with corticosteroid therapy: spanish multicentre study
11. THU-155 Incidence of fungal and other opportunistic infections in patients with autoimmune hepatitis: a spanish multicentre study
12. THU461 - Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis
13. SAT-484 - Diagnostic performance of non-invasive fibrosis markers in patients with immune-mediated disease and hepatic steatosis
14. THU076 - The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression
15. THU074 - Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors
16. OS157 - Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
17. Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC)
18. Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)
19. Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry
20. Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity
21. FRI277 - Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease
22. FRI055 - Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population
23. SAT-485-European cliolangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer
24. SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis
25. SAT-296-Oxidized LDL is a distinctive biomarker of NASH independently of liver fibrosis in patients with NAFLD
26. PS-011-New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease
27. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
28. SAT-507 - Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity
29. SAT-508 - Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry
30. FRI-164 - Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)
31. THU-206 - Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC)
32. PS-179 - Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice
33. Overexpression of Mirna-506 in Human Cholangiocytes Causes Primary Biliary Cholangitis-Like Features including Mitochondrial Dysfunction and Increased Sensitivity to Apoptosis
34. P1182 : MIR-506 is upregulated by pro-inflammatory cytokines in human cholangiocytes and inhibits cell proliferation and adhesion
35. O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC
36. THU-074 - Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
37. SAT-365 - Overexpression of Mirna-506 in Human Cholangiocytes Causes Primary Biliary Cholangitis-Like Features including Mitochondrial Dysfunction and Increased Sensitivity to Apoptosis
38. FRI-065 - SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumour Suppressor in Cholangiocarcinoma
39. P1183 : Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease
40. miR-21-5p promotes NASH-related hepatocarcinogenesis.
41. Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease.
42. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.